Holen Sie sich die Stockscreener-App
2.67
0.38%
0.010
Handel nachbörslich:
2.74
0.07
+2.62%
Schlusskurs vom Vortag:
$2.66
Offen:
$2.64
24-Stunden-Volumen:
41,474
Relative Volume:
0.61
Marktkapitalisierung:
$84.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.48M
KGV:
-6.8462
EPS:
-0.39
Netto-Cashflow:
$-7.93M
1W Leistung:
+1.52%
1M Leistung:
+3.49%
6M Leistung:
-13.87%
1J Leistung:
-10.10%
1-Tages-Spanne:
$2.60
$2.79
1-Wochen-Bereich:
$2.5301
$2.79
52-Wochen-Spanne:
$2.07
$4.20
Anixa Biosciences Inc Stock (ANIX) Company Profile
Firmenname
Anixa Biosciences Inc
Sektor
Branche
Telefon
408-708-9808
Adresse
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Vergleichen Sie ANIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.67 | 84.68M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-21 | Eingeleitet | Maxim Group | Buy |
| 2022-12-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-04-12 | Eingeleitet | H.C. Wainwright | Buy |
Anixa Biosciences Inc Aktie (ANIX) Neueste Nachrichten
Anixa Biosciences Announces Poster Presentation on Ovarian Cance - GuruFocus
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting - Stock Titan
Renaissance Technologies LLC Has $34,000 Stock Holdings in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences, Inc. (NASDAQ:ANIX) Shares Acquired by LPL Financial LLC - Defense World
Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual B - GuruFocus
Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th - Nasdaq
ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up - MSN
ANIXAnixa Biosciences Inc Latest Stock News & Market Updates - Stock Titan
Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center & American Association of Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium - Seeking Alpha
Anixa Biosciences (ANIX) Secures Patent to Advance CAR-T Cancer Therapy | ANIX Stock News - GuruFocus
Anixa Biosciences Receives Notice of Allowance from U.S. Patent - GuruFocus
Anixa Biosciences- Receives Notice Of Allowance For Car-T Technology Patent - marketscreener.com
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio | ANIX Stock News - GuruFocus
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio - Finansavisen
Indo-Asian News Service - Indo-Asian News Service (IANS)
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting - marketscreener.com
Anixa Biosciences (NASDAQ:ANIX) Earns “Buy” Rating from D. Boral Capital - Defense World
Anixa Biosciences Stock Price, Quotes and Forecasts - Benzinga
Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Anixa gains US patent for breast cancer vaccine technology - Investing.com Australia
Anixa gains US patent for breast cancer vaccine technology By Investing.com - Investing.com Canada
Anixa Biosciences Shares Rise After Notice of Patent Allowance for Breast Cancer Vaccine - marketscreener.com
EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent - AOL.com
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology - BioSpace
Anixa Biosciences stock rises on patent win (ANIX:NASDAQ) - Seeking Alpha
Anixa Biosciences Receives Notice Of Allowance From U.S. Patent And Trademark Office - MarketScreener
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
EF Hutton Initiates Coverage of Anixa Biosciences (ANIX) with Buy Recommendation - MSN
Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th - Quantisnow
Anixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from D. Boral Capital - Defense World
What is HC Wainwright’s Forecast for ANIX Q1 Earnings? - Defense World
Anixa Biosciences’ (ANIX) Buy Rating Reaffirmed at HC Wainwright - Defense World
EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines - AOL.com
Anixa Enters Letter of Intent to Develop Verdi's AI-Guided Cancer Vaccines - MarketScreener
Anixa Biosciences Enters Letter of Intent with VERDI Solutions t - GuruFocus
VERDI Grants Anixa 6-month Right To Negotiate Transaction For Development Of VERDI's Cancer Vaccines - Nasdaq
Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines - Marketscreener.com
Anixa secures US patent for ovarian cancer vaccine tech By Investing.com - Investing.com Australia
EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine - AOL.com
Anixa secures US patent for ovarian cancer vaccine tech - Investing.com India
Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine - Marketscreener.com
Maxim Group Begins Coverage on Anixa Biosciences (NASDAQ:ANIX) - Defense World
Finanzdaten der Anixa Biosciences Inc-Aktie (ANIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):